Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 9—September 2003

Research

Ehrlichia chaffeensis Infections among HIV-infected Patients in Human Monocytic Ehrlichiosis–Endemic Area

Thomas R. Talbot*Comments to Author , James A. Comer†, and Karen C. Bloch*
Author affiliations: *Vanderbilt University School of Medicine, Nashville, Tennessee, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table

Baseline characteristics of study cohort of HIV-positive persons residing in Tennesseea

Characteristic N (% or range)
Age (mean, y)
38.8 (21–75)
Sex

Male
107 (80.5%)
Female
26 (19.5%)
Baseline CD4 count (median, cells/mm3)
370 (6–1,200)
Baseline viral load (median, copies/dL)
1,003 (<400–>750,000)
On prophylaxis

HAART
122 (91.7%)
OI prophylaxis
70 (52.6%)
PCP prophylaxisb
66 (49.6%)
MAC prophylaxisc
31 (23.3%)
Average number of clinic visitsd
4.75 (1–13)
Treated with antibiotic therapyd,e
40/133 (30.1%)
Treated with doxycyclined
14/133 (10.5%)
Hospitalizedd 7/133 (5.3%)

          aHAART, highly active antiretroviral therapy; OI, opportunistic infection; PCP, Pneumocystis carinii pneumonia; MAC, Mycobacterium avium complex.
          bPCP prophylaxis: use of trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine therapy.
          cMAC prophylaxis: use of azithromycin or clarithromycin therapy.
          dDuring the study period.
          eAntibiotics used to treat the ongoing clinical symptoms; persons taking antibiotic therapy specifically for OI prophylaxis alone were not included.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO